Open AccessEverolimus‐eluting bioabsorbable vascular scaffolds ( BVS ) versus everolimus‐eluting metallic stents ( EES ) at 3 years: Systematic review and meta‐analysis
Author(s) -
Medveczky David,
O'Loughlin Aiden
Publication year - 2018
Publication title -
medical devices & sensors
Language(s) - English
Resource type - Journals
ISSN - 2573-802X
DOI - 10.1002/mds3.10008
Subject(s) - medicine , everolimus , meta analysis , target lesion , stent , odds ratio , clinical endpoint , myocardial infarction , thrombosis , surgery , randomized controlled trial , bare metal , percutaneous coronary intervention , restenosis
Background This systematic review and meta‐analysis aimed to assess the efficacy and safety of the Absorb bioabsorbable vascular scaffold ( BVS ) versus everolimus‐eluting metallic stents ( EES ) at 3 years. Methods We searched MEDLINE , EMBASE , CENTRAL and relevant websites for articles published between 30 November 2006 and 18 December 2017. The primary efficacy outcome was target lesion revascularization (TLR), and the primary safety outcome was definite or probable stent (scaffold) thrombosis. Secondary outcomes included target lesion failure, myocardial infarction (MI), death, all revascularization and a patient‐oriented composite end‐point. We derived odds ratios ( OR s) for the outcomes according to a fixed‐effects model. His study was registered with PROSPERO ( CRD 42017084290). Results We included five trials comprising data for 3,575 patients randomized to receive BVS ( n = 2,256) or EES ( n = 1,319). Patients treated with the BVS had a non‐statistically significant increased risk of TLR ( OR 1.30 [95% CI 0.95–1.78]; p = 0.10). Patients treated with the BVS had a higher risk of definite or probable stent thrombosis ( OR 2.68 [95% CI 1.57–4.58]; p < 0.001), target lesion failure (1.41 [1.12–1.78]; p = 0.004), MI (1.49 [1.13–1.98]; p = 0.005) and a patient‐oriented composite end‐point (1.21 [1.01–1.44]; p = 0.038) than those treated with an EES . Patients treated with the BVS had no statistically significant difference in death (0.80 [0.51–1.25]; p = 0.325) and all revascularization (1.12 [0.91–1.40]; p = 0.052) compared to those treated with an EES . Conclusion Everolimus‐eluting bioabsorbable vascular scaffolds are inferior to everolimus‐eluting metallic stents at 3 years.